Financial Comparison: Cytosorbents (CTSO) and Its Rivals

Cytosorbents (NASDAQ:CTSO) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Cytosorbents to similar companies based on the strength of its profitability, analyst recommendations, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings for Cytosorbents and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1	1	2	0	2.25
Cytosorbents Competitors	4266	10511	18262	826	2.46

Cytosorbents presently has a consensus price target of $74.83, suggesting a potential upside of 1,540.72%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 17.95%. Given Cytosorbents’ higher probable upside, equities research analysts clearly believe Cytosorbents is more favorable than its peers.

Volatility & Risk

Cytosorbents has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Cytosorbents’ peers have a beta of 2.56, meaning that their average stock price is 156% more volatile than the S&P 500.

Institutional and Insider Ownership

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cytosorbents and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
Cytosorbents Competitors	-278.16%	-150.10%	-21.89%

Earnings & Valuation

This table compares Cytosorbents and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cytosorbents	$37.06 million	-$8.20 million	-0.79
Cytosorbents Competitors	$1.89 billion	$138.79 million	11.24

Cytosorbents’ peers have higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Cytosorbents peers beat Cytosorbents on 11 of the 13 factors compared.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.